Company Anticipates 2026 Revenues of $60M to $62M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2026
0mins
Should l Buy TLSI?
The Company anticipates 2026 revenues in the range of $60 million to $62 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLSI
Wall Street analysts forecast TLSI stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.180
Low
10.00
Averages
11.92
High
16.00
Current: 4.180
Low
10.00
Averages
11.92
High
16.00
About TLSI
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TriSalus Publishes Liver Tumor Research Findings
- Drug Delivery Innovation: TriSalus's research indicates that the Pressure-Enabled Drug Delivery™ (PEDD™) technology using the TriNav® Infusion System significantly enhances the intratumoral distribution of nelitolimod in liver tumor models compared to conventional microcatheter delivery, potentially transforming tumor treatment strategies.
- Enhanced Immune Activity: The application of PEDD was associated with reduced levels of immunosuppressive myeloid-derived suppressor cells (MDSCs) and increased infiltration of cytotoxic CD8+ T cells within the tumor microenvironment, demonstrating the technology's potential in activating local immune responses.
- Tumor Growth Suppression: In murine liver metastasis models, nelitolimod delivered via PEDD significantly reduced tumor growth rates, indicating the effectiveness of this technology in enhancing immunotherapy outcomes.
- Strategic Implications: The findings support TriSalus's strategy of combining PEDD with locoregional immunotherapy, potentially offering new treatment options for patients with difficult-to-treat solid tumors and further solidifying the company's leadership position in oncology.
See More
TriSalus Life Sciences Reports Strong Q4 2025 Earnings with Strategic Growth Plans
- Significant Revenue Growth: TriSalus reported Q4 2025 revenues of $13.2 million, a 60% year-over-year increase, with full-year revenues reaching $45.2 million, up 53%, exceeding the 2025 revenue growth guidance and demonstrating commercial success driven by the expansion of the PEDD platform and TriNav product suite.
- Successful Financing and Strategic Investment: The company raised $46 million through a public offering that was more than 2x oversubscribed, attracting experienced healthcare investors, indicating strong market confidence in the long-term value of the PEDD platform while providing funding for future clinical studies and sales infrastructure expansion.
- Product Portfolio Expansion: TriSalus expanded its product offerings from 2 core products at the beginning of 2025 to 7 products entering 2026, aiming to drive more procedures per account and solidify its position as a single-source partner, targeting a $480 million liver embolization market.
- Future Outlook and Guidance: Management reaffirmed its revenue guidance for 2026 at $60 million to $62 million, with expectations for significant revenue growth in the second half of the year, reflecting a proactive investment strategy in sales organization expansion and new product launches.
See More
TriSalus (TLSI) Q4 2025 Earnings Call Transcript
See More
TriSalus Reports Q4 2025 Financial Results with Revenue Growth
- Financial Performance: TriSalus reported a Q4 2025 GAAP EPS of -$0.21, missing expectations by $0.07, indicating challenges in profitability despite a strong revenue growth of 59.8% to $13.2 million, reflecting robust market demand.
- Gross Margin Improvement: The gross margin increased to 86.7% in Q4, up from 85.3% in Q4 2024, demonstrating effective cost control and pricing strategies that enhance overall profitability and operational efficiency.
- Adjusted EBITDA Progress: Adjusted EBITDA improved from a loss of $5.7 million in Q4 2024 to a loss of $0.9 million, indicating positive strides in operational efficiency and cost management, potentially laying the groundwork for future profitability.
- Capital Raising: Subsequent to Q4, the company raised $46 million in gross proceeds through a public offering to support ongoing growth, enhancing its financial flexibility and competitive positioning in the market.
See More
TriSalus Life Sciences Announces Public Offering of Common Stock
- Public Offering Announcement: TriSalus Life Sciences has announced plans to conduct an underwritten public offering of its common stock, with all shares to be issued and sold by the company, which is expected to provide new funding sources to support its R&D and operations.
- Underwriter Option: The company intends to grant underwriters a 30-day option to purchase up to 15% additional shares, a strategy designed to enhance market acceptance of the offering and increase fundraising flexibility.
- Innovative Treatment Focus: TriSalus Life Sciences is concentrating on innovative approaches for thyroid artery embolization and tumor-targeted therapies, and the public offering will provide necessary funding to further develop these cutting-edge treatments.
- Financial Context: Historical financial data indicates that TriSalus Life Sciences' funding needs are closely tied to its R&D expenditures and market expansion plans, and this offering will help alleviate financial pressures and drive long-term growth for the company.
See More
TriSalus Board Changes and New Appointment
- Board Member Change: TriSalus announced the resignation of Dr. Arjun Desai from the Board, expressing gratitude for his contributions during a critical development phase, highlighting the company's commitment to leadership stability.
- New Board Appointment: Michael P. Stansky has been appointed as a new board member effective February 4, 2026, bringing 40 years of experience in healthcare investment, which may provide new strategic insights and resources for the company.
- Investment Management Expertise: Stansky previously served as Managing Director at Tudor Investment Corporation, overseeing long/short equity investments, and his extensive investment management background is expected to enhance TriSalus's performance in capital markets and value creation.
- Platform Potential Recognition: Stansky acknowledged the potential of TriSalus's PEDD™ platform to significantly improve treatment outcomes for patients with solid tumors, indicating the company's strategic focus on innovative drug delivery technologies.
See More
TriSalus Publishes Liver Tumor Research Findings
- Drug Delivery Innovation: TriSalus's research indicates that the Pressure-Enabled Drug Delivery™ (PEDD™) technology using the TriNav® Infusion System significantly enhances the intratumoral distribution of nelitolimod in liver tumor models compared to conventional microcatheter delivery, potentially transforming tumor treatment strategies.
- Enhanced Immune Activity: The application of PEDD was associated with reduced levels of immunosuppressive myeloid-derived suppressor cells (MDSCs) and increased infiltration of cytotoxic CD8+ T cells within the tumor microenvironment, demonstrating the technology's potential in activating local immune responses.
- Tumor Growth Suppression: In murine liver metastasis models, nelitolimod delivered via PEDD significantly reduced tumor growth rates, indicating the effectiveness of this technology in enhancing immunotherapy outcomes.
- Strategic Implications: The findings support TriSalus's strategy of combining PEDD with locoregional immunotherapy, potentially offering new treatment options for patients with difficult-to-treat solid tumors and further solidifying the company's leadership position in oncology.
See More
TriSalus Life Sciences Reports Strong Q4 2025 Earnings with Strategic Growth Plans
- Significant Revenue Growth: TriSalus reported Q4 2025 revenues of $13.2 million, a 60% year-over-year increase, with full-year revenues reaching $45.2 million, up 53%, exceeding the 2025 revenue growth guidance and demonstrating commercial success driven by the expansion of the PEDD platform and TriNav product suite.
- Successful Financing and Strategic Investment: The company raised $46 million through a public offering that was more than 2x oversubscribed, attracting experienced healthcare investors, indicating strong market confidence in the long-term value of the PEDD platform while providing funding for future clinical studies and sales infrastructure expansion.
- Product Portfolio Expansion: TriSalus expanded its product offerings from 2 core products at the beginning of 2025 to 7 products entering 2026, aiming to drive more procedures per account and solidify its position as a single-source partner, targeting a $480 million liver embolization market.
- Future Outlook and Guidance: Management reaffirmed its revenue guidance for 2026 at $60 million to $62 million, with expectations for significant revenue growth in the second half of the year, reflecting a proactive investment strategy in sales organization expansion and new product launches.
See More
TriSalus (TLSI) Q4 2025 Earnings Call Transcript
See More
TriSalus Reports Q4 2025 Financial Results with Revenue Growth
- Financial Performance: TriSalus reported a Q4 2025 GAAP EPS of -$0.21, missing expectations by $0.07, indicating challenges in profitability despite a strong revenue growth of 59.8% to $13.2 million, reflecting robust market demand.
- Gross Margin Improvement: The gross margin increased to 86.7% in Q4, up from 85.3% in Q4 2024, demonstrating effective cost control and pricing strategies that enhance overall profitability and operational efficiency.
- Adjusted EBITDA Progress: Adjusted EBITDA improved from a loss of $5.7 million in Q4 2024 to a loss of $0.9 million, indicating positive strides in operational efficiency and cost management, potentially laying the groundwork for future profitability.
- Capital Raising: Subsequent to Q4, the company raised $46 million in gross proceeds through a public offering to support ongoing growth, enhancing its financial flexibility and competitive positioning in the market.
See More
TriSalus Life Sciences Announces Public Offering of Common Stock
- Public Offering Announcement: TriSalus Life Sciences has announced plans to conduct an underwritten public offering of its common stock, with all shares to be issued and sold by the company, which is expected to provide new funding sources to support its R&D and operations.
- Underwriter Option: The company intends to grant underwriters a 30-day option to purchase up to 15% additional shares, a strategy designed to enhance market acceptance of the offering and increase fundraising flexibility.
- Innovative Treatment Focus: TriSalus Life Sciences is concentrating on innovative approaches for thyroid artery embolization and tumor-targeted therapies, and the public offering will provide necessary funding to further develop these cutting-edge treatments.
- Financial Context: Historical financial data indicates that TriSalus Life Sciences' funding needs are closely tied to its R&D expenditures and market expansion plans, and this offering will help alleviate financial pressures and drive long-term growth for the company.
See More
TriSalus Board Changes and New Appointment
- Board Member Change: TriSalus announced the resignation of Dr. Arjun Desai from the Board, expressing gratitude for his contributions during a critical development phase, highlighting the company's commitment to leadership stability.
- New Board Appointment: Michael P. Stansky has been appointed as a new board member effective February 4, 2026, bringing 40 years of experience in healthcare investment, which may provide new strategic insights and resources for the company.
- Investment Management Expertise: Stansky previously served as Managing Director at Tudor Investment Corporation, overseeing long/short equity investments, and his extensive investment management background is expected to enhance TriSalus's performance in capital markets and value creation.
- Platform Potential Recognition: Stansky acknowledged the potential of TriSalus's PEDD™ platform to significantly improve treatment outcomes for patients with solid tumors, indicating the company's strategic focus on innovative drug delivery technologies.
See More
